OCT 16, 2018 10:00 PM PDT

Potential Targeted Treatment for Crohn Disease

WRITTEN BY: Nouran Amin

Emerging as a global disease with rates increasing the past 5 decades, Crohn’s disease (CD) is the chronic inflammation of the intestinal tract.

Now, recent research at Cornell University and University of North Carolina (UNC) is a step closer to advancing drug treatments for CD patients. Such research proposes the potential targeting of a key molecule, called microRNA-31 (miR-31), which can predict if a patient has subtype 1 or subtype 2 of Crohn’s disease. This is particularly crucial because patients with subtype 1, unlike subtype 2, will often not respond to treatments which can lead to the surgical interventions for strictures – the extreme narrowing of the gut. With clinical markers like miR-31, healthcare providers may be able to better asses a CD patient if they should consider pre-emptive surgery before the condition worsens.

“We are not at the point at which we are able to perform personalized medicine on this, but at the very least we think it can lead to better clinical trial designs,” says Praveen Sethupathy, senior co-author of the study.

Previously, clinical trials assessing a new drug for CD has grouped all patients together causing inconsistent results. However, using miR-31, scientists are now able to separate individuals with CD into subtypes for better drug assessment. The results of the study published in the journal JCI Insight.

Credit: Drug Target Review

“Our study hints that it’s not only that miR-31 could be a predictive indicator of clinical outcome, but also that it could be functionally relevant in driving the disease,” explains Sethupathy.

Researchers are now hopeful for future studies that will determine the exact role of miR-31 in gut biology. “Our long-term goal, extending the work of this study, is to better understand at the molecular level why CD is so different in its presentation across patients, and to use this knowledge to develop more effective therapies,” says Terrence Furey, an associate professor of genetics.

Source: Drug Target Review

About the Author
  • Nouran enjoys writing on various topics including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
SEP 21, 2019
Cell & Molecular Biology
SEP 21, 2019
Progress on a Potential Drug for Inflammatory Disease
A team of researchers is trying to develop a treatment for chronic inflammatory disorders by inhibiting a complex called the NLRP3 inflammasome....
SEP 21, 2019
Drug Discovery & Development
SEP 21, 2019
Remote Controlled Drug Delivery?
According to the CDC, chronic diseases although the most common are preventable of all medical problems. Chronic diseases ranging from arthritis to heart d...
SEP 21, 2019
Microbiology
SEP 21, 2019
Picturing a New Kind of Antibiotic
Scientists have deciphered the X-ray crystal structure of an enzyme that generates a unique broad spectrum antibiotic called obafluorin....
SEP 21, 2019
Chemistry & Physics
SEP 21, 2019
Chemists Synthesized Effective Antidote For Uranium Poisoning
Uranium poisoning is unusual to the general population but does happen to miners, mineral mill and fabrication workers. Through inhaling and ingestion, ura...
SEP 21, 2019
Drug Discovery & Development
SEP 21, 2019
Drug Reduces Heart Attacks in Diabetic Patients
Recent results from a clinical trial that evaluated the addition of a drug called ‘ticagrelor’ to aspirin were shown to improve clinical outcom...
SEP 21, 2019
Drug Discovery & Development
SEP 21, 2019
How Does Ketamine Treat Depression?
In recent years, ketamine has received growing interest for its neuroprotective effects. Known to alleviate symptoms of depression in just hours whereas co...
Loading Comments...